Liposomal trichostatin A: Therαpeutic potential in hormone-dependent and -independent breast cancer xenograft models

Hormone Molecular Biology and Clinical Investigation

Volumn 6, Issue 2, 2011, Pages 215-225

  Urbinati, Giorgia ^a,b   Marsaud, Véronique ^a,c   Vergnaud Gauduchon, Juliette ^a,c   Renoir, Jack Michel ^a,c,d   Nicolas, Valérie ^c  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c IPSIT   (France)

^d INSERM   (France)

Author keywords

breast cancer; liposomes; trichostatin A; xenografts

Indexed keywords

EID: 84988539832     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.005     Document Type: Article

References (78)

1. Koehler KF., Helguero LA., Haldosen LA., Warner M., Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 2005;26:465-78.
2. Helguero LA., Faulds MH., Gustafsson JA., Haldosen LA. Estrogen receptors alfa (ERα) and beta (ERΒ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005;24:6605-16.
3. Pettersson K., Delaunay F., Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 2000;19:4970-8.
4. Strom A., Hartman J., Foster JS., Kietz S., Wimalasena J., Gustafsson JA. Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566-71.
5. Lazennec G. Estrogen receptor β, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006;231: 151-7.
6. Ali S., Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2: 101-12.
7. Keen JC., Davidson NE. The biology of breast carcinoma. Cancer 2003;97(3 Suppl):825-33.
8. Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/ human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12: 1061s-8s.
9. Archer SY., Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-4.
10. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hype-racetylation. Gene Expr 1996;5:245-53.
11. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/ Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241:142-50.
12. Marks P., Rifkind RA., Richon VM., Breslow R., Miller T., Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
13. Palmieri C., Coombes RC., Vigushin DM. Targeted histone dea-cetylase inhibition for cancer prevention and therapy. Prog Drug Res 2005;63:147-81.
14. Minucci S., Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
15. Bolden JE., Peart MJ., Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
16. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
17. Roy S., Packman K., Jeffrey R., Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005;12:482-91.
18. Fu M., Rao M., Wang C., Sakamaki T., Wang J., Di Vizio D., Zhang X., Albanese C., Balk S., Chang C., Fan S., Rosen E., Palvimo JJ., Janne OA., Muratoglu S., Avantaggiati ML., Pestell RG. Acety-lation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23: 8563-75.
19. Wang C., Fu M., Angeletti RH., Siconolfi-Baez L., Reutens AT., Albanese C., Lisanti MP., Katzenellenbogen BS., Kato S., Hopp T., Fuqua SA., Lopez GN., Kushner PJ., Pestell RG. Direct acet-ylation of the estrogen receptor a hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276: 18375-83.
20. Kim MY., Hsiao SJ., Kraus WL. A role for coactivators and his-tone acetylation in estrogen receptor a-mediated transcription initiation. EMBO J 2001;20:6084-94.
21. Reid G., Hubner MR., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic., proteasome-medi-ated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695-707.
22. Duong V., Licznar A., Margueron R., Boulle N., Busson M., Lacroix M., Katzenellenbogen BS., Cavailles V., Lazennec G. ERΑ and ERΒ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006;25: 1799-806.
23. Duong V., Bret C., Altucci L., Mai A., Duraffourd C., Loubersac J., Harmand PO., Bonnet S., Valente S., Maudelonde T., Cavailles V., Boulle N. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 2008;6:1908-19.
24. Kim TY., Bang YJ., Robertson KD. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006;1:14-23.
25. Keen JC., Yan L., Mack KM., Pettit C., Smith D., Sharma D., Davidson NE. A novel histone deacetylase inhibitor., scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat 2003;81:177-86.
26. Bhat-Nakshatri P., Wang G., Appaiah H., Luktuke N., Carroll JS., Geistlinger TR., Brown M., Badve S., Liu Y., Nakshatri H. AKT alters genome-wide estrogen receptor a binding and impacts estrogen signaling in breast cancer. Mol Cell Biol 2008;28: 7487-503.
27. Hamner JB., Sims TL., Cutshaw A., Dickson PV., Rosati S., McGee M., Ng CY., Davidoff AM. The efficacy of combination therapy using adeno-associated virus-interferon β and trichostatin A in vitro and in a murine model of neuroblastoma. J Pediatr Surg 2008;43:177-82; discussion 182-3.
28. Vanhaecke T., Papeleu P., Elaut G., Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 2004;11: 1629-43.
29. Elaut G., Torok G., Vinken M., Laus G., Papeleu P., Tourwe D., Rogiers V. Major phase I biotransformation pathways of trichostatin A in rat hepatocytes and in rat and human liver micro-somes. Drug Metab Dispos 2002;30:1320-8.
30. Urbinati G., Marsaud V., Plassat V., Fattal E., Lesieur S., Renoir JM. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy. Int J Pharm 2010;397:184-93.
31. Maillard S., Ameller T., Gauduchon J., Gougelet A., Gouilleux F., Legrand P., Marsaud V., Fattal E., Sola B., Renoir JM. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 2005;94:111-21.
32. Marsaud V., Gougelet A., Maillard S., Renoir JM. Various phos-phorylation pathways., depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability., proteasome-mediated stability., and transcriptional activity in human breast cancer cells. Mol Endo-crinol 2003;17:2013-27.
33. Plassat V., Martina MS., Barratt G., Menager C., Lesieur S. Ster-ically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm 2007;344:118-27.
34. Bouclier C., Marsaud V., Bawa O., Nicolas V., Moine L., Opolon P., Renoir JM. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor β and anti-oestrogen syn-ergistically induces tumor growth inhibition in human breast cancer xenografts. Breast Cancer Res Treat 2009;122:145-58.
35. Abramova MV., Pospelova TV., Nikulenkov FP., Hollander CM., Fornace AJ Jr., Pospelov VA. G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of β-catenin. J Biol Chem 2006;281:21040-51.
36. Alao JP., Lam EW., Ali S., Buluwela L., Bordogna W., Lockey P., Varshochi R., Stavropoulou AV., Coombes RC., Vigushin DM. Histone deacetylase inhibitor trichostatin A represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004;10:8094-104.
37. Archer SY., Meng S., Shei A., Hodin RA. p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95:6791-6.
38. Richon VM., Sandhoff TW., Rifkind RA., Marks PA. Histone dea-cetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-9.
39. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang HG., Richon V., Bhalla K. Activity of sube-roylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005;11:6382-9.
40. Liu A., Cerniglia GJ., Bernhard EJ., Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci USA 2001;98:6192-7.
41. Hodges-Gallagher L., Valentine CD., Bader SE., Kushner PJ. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxi-fen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007;105:297-309.
42. Sharma D., Saxena NK., Davidson NE., Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 2006;66:6370-8.
43. Jang ER., Lim SJ., Lee ES., Jeong G., Kim TY., Bang YJ., Lee JS. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor a-negative breast cancer cells to tamoxifen. Oncogene 2004;23:1724-36.
44. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., Herger B., Yang Y., Atadja P., Wu J., Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen recep-tor-a levels and transcriptional activity: a result of hyperacety-lation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007;13:4882-90.
45. Nakajima S., Niizeki H., Tada M., Nakagawa K., Kondo S., Okada F., Kobayashi M. Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231. Oncol Rep 2009;22:143-8.
46. Delarue FL., Adnane J., Joshi B., Blaskovich MA., Wang DA., Hawker J., Bizouarn F., Ohkanda J., Zhu K., Hamilton AD., Chel-lappan S., Sebti SM. Farnesyltransferase and geranylgeranyl-transferase I inhibitors upregulate RhoB expression by HDAC1 dissociation., HAT association and histone acetylation of the RhoB promoter. Oncogene 2007;26:633-40.
47. Sharma D., Blum J., Yang X., Beaulieu N., Macleod AR., Davidson NE. Release of methyl CpG binding proteins and histone dea-cetylase 1 from the estrogen receptor α (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 2005;19:1740-51.
48. Janicke RU., Sprengart ML., Wati MR., Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
49. Liang Y., Yan C., Schor NF. Apoptosis in the absence of caspase 3. Oncogene 2001;20:6570-8.
50. Moghimi SM., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics., opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-78.
51. Moghimi SM., Hunter AC., Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
52. Qiu L., Kelso MJ., Hansen C., West ML., Fairlie DP., Parsons PG. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999;80: 1252-8.
53. Hanahan D., Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
54. Liu TC., Castelo-Branco P., Rabkin SD., Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008; 16:1041-7.
55. Vigushin DM., Ali S., Pace PE., Mirsaidi N., Ito K., Adcock I., Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001;7:971-6.
56. Canes D., Chiang GJ., Billmeyer BR., Austin CA., Kosakowski M., Rieger-Christ KM., Libertino JA., Summerhayes IC. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 2005;113:841-8.
57. Dokmanovic M., Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
58. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer 2001;1:162-8.
59. Fritz G., Kaina B. Ras-related GTPase RhoB represses NF-kB signaling. J Biol Chem 2001;276:3115-22.
60. Wang L., Yang L., Luo Y., Zheng Y. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells. J Biol Chem 2003;278:44617-25.
61. Renoir JM., Stella B., Ameller T., Connault E., Opolon P., Marsaud V. Improved anti-tumoral capacity of mixed and pure anti-oes-trogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J Steroid Biochem Mol Biol 2006;102:114-27.
62. Yuan F., Leunig M., Huang SK., Berk DA., Papahadjopoulos D., Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6.
63. Margueron R., Licznar A., Lazennec G., Vignon F., Cavailles V Oestrogen receptor a increases p21WAF1/CIP1 gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 2003;179:41-53.
64. Couderc B., Pradines A., Rafii A., Golzio M., Deviers A., Allal C., Berg D., Penary M., Teissie J., Favre G. In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther 2008;15:456-64.
65. Mazieres J., Tillement V., Allal C., Clanet C., Bobin L., Chen Z., Sebti SM., Favre G., Pradines A. Geranylgeranylated., but not farnesylated., RhoB suppresses Ras transformation of NIH-3T3 cells. Exp Cell Res 2005;304:354-64.
66. Doisneau-Sixou SF., Sergio CM., Carroll JS., Hui R., Musgrove EA., Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003;10:179-86.
67. Jaffe AB., Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002;84:57-80.
68. Karlsson R., Pedersen ED., Wang Z., Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796: 91-8.
69. Jahner D., Hunter T. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor., and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 1991;11:3682-90.
70. Heasman SJ., Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008;9:690-701.
71. Adnane J., Muro-Cacho C., Mathews L., Sebti SM., Munoz-Anto-nia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 2002;8: 2225-32.
72. Buck MB., Pfizenmaier K., Knabbe C. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-acti-vated protein kinase and transforming growth factor-p pathways in human breast cancer cells. Mol Endocrinol 2004;18:1643-57.
73. Li H., Liu JP. Mechanisms of action of TGF-Β in cancer: evidence for Smad3 as a repressor of the hTERT gene. Ann NY Acad Sci 2007;1114:56-68.
74. Muraoka-Cook RS., Dumont N., Arteaga CL. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s-43s.
75. Bellizzi A., Mangia A., Chiriatti A., Petroni S., Quaranta M., Schit-tulli F., Malfettone A., Cardone RA., Paradiso A., Reshkin SJ. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int J Mol Med 2008;22:25-31.
76. Fritz G., Brachetti C., Bahlmann F., Schmidt M., Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002;87:635-44.
77. Fan J., Yin WJ., Lu JS., Wang L., Wu J., Wu FY., Di GH., Shen ZZ., Shao ZM. ER a negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008;134:883-90.
78. Urbinati G., Audisio D., Marsaud V., Plassat V., Arpicco S., Sola B., Fattal E., Renoir JM. Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model. Pharm Res 2009;27:327-39.